The AEGEA Vapor System is the first endometrial ablation system specifically designed to be used in the doctor’s office.

Adaptive Vapor Ablation

The AEGEA Vapor System uses Adaptive Vapor Ablation, an innovative solution for endometrial ablation to treat menorrhagia.

After nearly a decade of research and development, a new approach to treat menorrhagia has arrived. By harnessing the ability of natural water vapor to efficiently conform to the unique differences of a woman’s anatomy, AEGEA provides a treatment option for menorrhagia.

The AEGEA Vapor System is the first FDA-approved endometrial ablation system specifically designed for the doctor’s office. The AEGEA Vapor System is designed to be safe, simple, effective, and inclusive.


Only FDA-approved,device with patented Smart SealTM and Integrity ProTM technology

Vapor Probe Insertion
  • slender, soft, flexible tip
  • cervical collar aids in placing the Vapor Probe just beyond the internal cervical os
  • no requirement to touch the uterine fundus
  • cervical dilation not required
  • provides automated real-time monitoring with active management of uterine and cervical seal
  • monitors balloon pressure, uterine pressure and cervical temperature and is designed to confine vapor to the uterine cavity during treatment
  • includes new patented secondary safety check above and beyond the integrity test to provide an added level of confidence
  • Uterine Cavity Integrity Test uniquely includes confirmation of correct placement of the device
  • vapor will not be initiated until the safety checks are successfully completed


Fully automated safety and delivery system provides peace of mind for in-office procedure.

  • a 4-minute procedure, which includes 2 minutes of vapor treatment, can be performed in-office without need for general anesthesia no arrays to deploy, no treatment balloons to inflate, no ice-balls to form
  • no intracavitary manipulation and no dilation required
  • universal treatment parameters obviate need for generator programming
  • no concurrent ultrasound required


Effectiveness supported by significant bleeding reduction, improved quality of life and high patient satisfaction.

  • 6X reduction in menstrual bleeding per Pivotal Study criteriaa
  • 90% had bleeding reduced by ≥50%
  • 85% had bleeding that was reduced to a normal level or less per scientific literatureb
  • 99% experienced an improvement in quality of life 12 months post-treatment
  • 93% would recommend the procedure to a friend
  • 91% were satisfied or very satisfied 12 months after the procedure


Conforms to uterine cavities with unique differences.

  • uterine cavities up to 12 cm in length
  • any uterine width
  • uterine cavities with certain types of fibroids
  • patients with a prior low transverse cesarean section
  • in the presence of Essure®
A natural choice. A new freedom.